Open in interactive viewer → charts, metric popovers & call review

Twist Bioscience's First Profit, And the 44% Drawdown That Greeted It

Management says orders will triple again — then guides AI revenue to grow ~70%. That gap, not the EBITDA milestone, is what the market is pricing.
TWST · Earnings Call · 2026-11-12

A milestone nobody is celebrating

Twist Bioscience crossed the line it has been promising for years: positive adjusted EBITDA of $2.2 million in the fiscal fourth quarter. Revenue for the quarter was $126.6 million, up 28% year-over-year and 7% sequentially — the fifteenth consecutive quarter of sequential growth — and full-year revenue reached $459.4 million, up 22% and more than $30 million above the original fiscal 2026 guidance. Gross margin finished at 53.1% for the quarter and 52.4% for the year. And yet the stock is a mess. Twist printed a high of $205.00 on October 5, 2026, and has since fallen 44.3% in nine trading days' worth of damage — the recent tape reads bluntly: up 85% over fifteen weeks, then down 25% in nine days. The report lands squarely in that collapse. That is the tension worth unpacking: the fundamentals inflected, and the multiple didn't.

The $100 million confession

The arithmetic that matters is simple. AI revenue went from $21.5 million in fiscal 2025 to $59.1 million in fiscal 2026 — 175% growth. For fiscal 2027, management guides total revenue of $550–560 million (about 21% growth) including $100 million from AI drug discovery. That is roughly 69% growth on a business that just compounded at 175%. Every analyst on the call found the same seam. Subbu Nambi of Guggenheim went straight at it: the target is the "same number you've been talking about for a while," now off a much higher base — "why would growth moderate?"“Our initial guidance is for $100 million in AI drug discovery revenue... those are programs that we can forecast with high confidence today. And so we see that there is meaningful upside on top of that assumption.” — Emily Leproust, CEO and Co-Founder · 2026-11-12 Puneet Souda of Leerink pushed harder, asking whether the ~70% revenue guide against triple-digit order growth implied a timing mismatch between bookings and recognition. Emily Leproust's answer was emphatic and, read carefully, evasive:

By triple-digit percent growth, we mean triple-digit percent growth... what we can take to the bank today guaranteed is $100 million. And we also see a lot of upside. Some of that upside if we want to realize it, we need to add the capacity. And so that's right. It's in our hands.

Emily Leproust, CEO and Co-Founder · 2026-11-12
So the ceiling is capacity, not demand. That is a good problem — but it is also the exact claim the company made a quarter ago, when it committed to "triple-digit percentage growth that we see in AI-enabled drug discovery that we know we're going to be able to deliver in 2026"“triple-digit percentage growth that we see in AI-enabled drug discovery” — Emily Leproust, CEO · 2026-08-03. The pattern is now established: a bold order-growth commitment, a conservative revenue number, and "upside" bridging the two. Investors have learned to discount the first and trade the second. What has genuinely changed is the description of the customer base. A year ago this was "dozens of accounts." Adam Laponis now notes “We've added even some of the [indiscernible] Magnificent 7 and some of the larger hyperscalers to the mix.” — Adam Laponis, Chief Financial Officer · 2026-11-12 The model building cohort that begins with $10K–$100K pilots and graduates to multi-million-dollar characterization orders is, per management, returning in repeat cycles — the run-rate discovery business, they argue, is larger than the initial data binge. That was already true in May: “the orders maybe each order may be a little bit smaller... but it's more of it” — Emily Leproust, Executive, likely CEO or similar senior role · 2026-05-04. The mechanism is not new. The scale is.

Building ahead of demand, and paying for it in the margin line

Here is the part the sell-side did not press hard enough. Twist raised roughly $425 million in net proceeds, ending the year with $582 million in cash — effective net cash of roughly $870 million, up 68% year-over-year. It now plans to spend about $150 million on capital expenditures across fiscal 2027–28 (roughly $75 million in FY27 alone) to expand capacity for more than $1 billion of annual revenue within existing facilities. That spending lands directly on the margin line. Guidance for fiscal 2027 is gross margin of 52.5%–53% — essentially flat — because new capacity depreciates before it fills. Laponis framed the trade-off without apology: “we'd rather run a $2 billion business at a 50% gross margin than a $1 billion business at a 60% gross margin.” — Adam Laponis, Chief Financial Officer · 2026-11-12 The step-up is visible in the machinery: DNA writers go from ten operating to sixteen, taking daily capacity from about 32 million oligos to north of 50 million. Capacity expansion is the whole investment case, and it is also why gross margin expansion pauses at 52–53% after climbing for two straight years. Two themes are genuinely new this quarter. MRD Express launched commercially two weeks before the call and, per Laponis, will contribute accelerating dollar growth off a small base; tumor-informed panels demanding thousands of probes per patient are precisely the workload that absorbs the new capacity. And nucleic acid therapeutics — mRNA, siRNA, personalized cancer therapy — got an entire slide and an explicit warning that it is a medium-to-long-dated option with almost nothing in the guide: “Very little is embedded in '27. Right now, we are servicing the clinical trials that are ongoing.” — Emily Leproust, CEO and Co-Founder · 2026-11-12 That is a seed planted, not a revenue line.

What management stopped saying

The loudest signal is an absence. A year ago, DNA data storage and the Atlas Data Storage spinout were the company's top-ranked themes — rank one and two in the fourth quarter of fiscal 2025. In this transcript they do not appear. Neither does the academic pricing promotion that dominated SynBio discussion for two quarters, nor the "air pocket" customer transition that management flagged for three consecutive calls. Those stories have been resolved or retired, and the narrative has narrowed to a single engine: AI drug discovery, supported by AI orders converting into recurring discovery work. The market read on the tape is less generous. Twist closed November 12 some 14.9x trailing revenue, up 144% year-over-year — a valuation that demands the upside management keeps hinting at but will not guide. Free cash flow was still negative $27 million in the last reported quarter, and the $150 million capex program means it stays negative through fiscal 2028. There is corroboration elsewhere in the tape. Azenta, reporting the same week, cited growth in Gene Synthesis and drug discovery as genuine demand pockets — Twist is not alone in articulating this, which cuts both ways: it validates the market and invites competition. Leproust's answer to GenScript, given in August, still stands as the bull case in one line: “we are the disruptor, not the other way around” — Emily Leproust, CEO · 2026-08-03. The verdict: a company that finally turned profitable, is spending that profit immediately on throughput, and is asking investors to trust a triple-digit order funnel while guiding the revenue below it. Fifteen quarters of sequential growth is real. So is a 44% drawdown into an earnings print. Both are the story.